EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Potent monoclonal antibodies against multidrug‐resistant hypervirulent Klebsiella pneumoniae

Yushan Jiang, Zhuolin Li, Yang Yang, Zihan He, Tyuji Hoshino, Vladislav Victorovich Khrustalev, Qing Zhu, Weiling Wu, Wei Zhao, Chenguang Shen, Shi Ouyang

Interdisciplinary Medicine · 2026-07 · 4 (4)

DOI: 10.1002/inmd.70115 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Interdisciplinary Medicine, online erschienen am 18.03.2026. Verfasst von Yushan Jiang und 10 weiteren Autor:innen. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Postdoctoral Science Foundation, National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multidrug‐resistant hypervirulent Klebsiella pneumoniae (MDR‐hvKP) infections present a therapeutic challenge owing to profound antibiotic resistance and the paucity of cross‐serotype protective strategies against distinct serovars (e.g., K1/K2). Mice were subcutaneously immunized with the viable, hypovirulent, multidrug‐resistant (MDR) strain Kp00198874 (serotype K64). Cross‐reactive monoclonal antibodies (mAbs) were derived using hybridoma technology. Immunization elicited cross‐serotype protective antibodies, ensuring 100% survival rates against lethal challenges posed by the K1/K2 serotype strains. In contrast to single neutralizing antibodies, mAbs 2D4 and 2E10 modulate phagocytic bacteria and immune responses. Prophylactic administration of mAbs conferred 100% survival rates against Kp‐GZ8 and significantly prolonged the median survival time against ATCC43816 cells. Therapeutic intervention with mAbs mitigated post‐infection pulmonary hemorrhage and inflammatory responses. mAbs 2D4 and 2E10 synergistically targeted capsular polysaccharide/protein epitopes to achieve cross‐serotype‐protective efficacy. This study established live Kp00198874 immunization as a novel platform for generating cross‐protective mAbs against lethal MDR‐hvKP, with 2D4 and 2E10 providing complementary mechanisms (rapid pathogen clearance and immunomodulation) through conserved epitope targeting, offering an antibody‐based alternative for resistant infections.

Förderung

  • China Postdoctoral Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Jiang, Y., Li, Z., Yang, Y., He, Z., Hoshino, T., Khrustalev, V. V., Zhu, Q., Wu, W., Zhao, W., Shen, C., & Ouyang, S. (2026). Potent monoclonal antibodies against multidrug‐resistant hypervirulent Klebsiella pneumoniae. Interdisciplinary Medicine, 4(4). https://doi.org/10.1002/inmd.70115

Vancouver

Jiang Y, Li Z, Yang Y, He Z, Hoshino T, Khrustalev VV, et al. Potent monoclonal antibodies against multidrug‐resistant hypervirulent Klebsiella pneumoniae. Interdisciplinary Medicine. 2026;4(4). doi:10.1002/inmd.70115

BibTeX
@article{Jiang2026,
  author = {Jiang, Yushan and Li, Zhuolin and Yang, Yang and He, Zihan and Hoshino, Tyuji and Khrustalev, Vladislav Victorovich and Zhu, Qing and Wu, Weiling and Zhao, Wei and Shen, Chenguang and Ouyang, Shi},
  title = {Potent monoclonal antibodies against multidrug‐resistant hypervirulent Klebsiella pneumoniae},
  journal = {Interdisciplinary Medicine},
  year = {2026},
  volume = {4},
  number = {4},
  doi = {10.1002/inmd.70115}
}
Kostenlos starten →